Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- befree-2016 importedOn "2016-02-19" NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion wasGeneratedBy ECO_0000203 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion wasDerivedFrom befree-2016 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion SIO_000772 23932550 NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion evidence source_evidence_literature NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.
- NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_assertion description "[Although the use of mipomersen and lomitapide is limited to severe familial hypercholesterolemia as a replacement for LDL-apheresis, PCSK9 inhibitors are likely to be more widely prescribed in patients at high risk for CVD, especially those who are resistant to or intolerant of high-intensity statin therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1100973.RAPSUgZyP3Se5lltXuy1yisMie0Z2kic8Q9xH_h0DgXOo130_provenance.